Pacira | PCRX - Cash And Equivalent

Stock Price
22.38
Daily Change
-1.08 -4.60%
Monthly
12.75%
Yearly
-11.82%
Q1 Forecast
22.50

Pacira reported $147.59M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Assertio Holdings USD 38.5M 8.59M Sep/2025
Astellas Pharma JPY 188.37B 8.51B Mar/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Cara Therapeutics USD 20.65M 13.57M Jun/2025
Coherus Biosciences USD 103.35M 113.54M Sep/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Xeris Pharmaceuticals USD 91.6M 32.32M Sep/2025
Xoma USD 143.9M 7.68M Jun/2024
Zoetis USD 2.08B 649M Sep/2025